Overview
Start/End Dates
Locations
Djavad Mowafaghian Centre for Brain Health
Name/Title
Christopher Mok, Research Coordinator
Phone
Email Address
Purpose of Study
In people with ALS, faster disease progression and decreased lifespan have been linked to immune system dysregulation and inflammatory processes. COYA302 is a subcutaneous injection drug therapy which has been shown to improve immune system regulation and suppress inflammation in people with ALS. This study will assess the safety, effects and long-term efficacy of COYA302 administered to patients with ALS.
The study consists of back-to-back treatment phases, extension phase optional. In initial phase, participants will randomly receive study drug, placebo (dummy) or mixed regimen of both; extension phase will randomly receive study drug or mixed regimen. Participants will complete up to 15 in-person visits (across both phases), each involving a combination of drug administration, blood collection, clinical assessments and procedures. There will be phone calls between visits to monitor participant safety and drug self-administration compliance.
Eligibility
Visit ClinicalTrials.gov for more information.
Disclaimer
Study Coordinators and Research Nurses cannot give medical advice over the phone. Telephone numbers and email addresses are provided for obtaining additional information on specific research studies only. If you have specific questions which require clinical expertise, please call your primary care physician.
In people with ALS, faster disease progression and decreased lifespan have been linked to immune system dysregulation and inflammatory processes. COYA302 is a subcutaneous injection drug therapy which has been shown to improve immune system regulation and suppress inflammation in people with ALS. This study will assess the safety, effects and long-term efficacy of COYA302 administered to patients with ALS.
The study consists of back-to-back treatment phases, extension phase optional. In initial phase, participants will randomly receive study drug, placebo (dummy) or mixed regimen of both; extension phase will randomly receive study drug or mixed regimen. Participants will complete up to 15 in-person visits (across both phases), each involving a combination of drug administration, blood collection, clinical assessments and procedures. There will be phone calls between visits to monitor participant safety and drug self-administration compliance.
Visit ClinicalTrials.gov for more information.
Study Coordinators and Research Nurses cannot give medical advice over the phone. Telephone numbers and email addresses are provided for obtaining additional information on specific research studies only. If you have specific questions which require clinical expertise, please call your primary care physician.
